Exozymes Inc. announced on June 24, 2026, that it received a $2 million grant from the National Institutes of Health (NIH). The funding is intended to support the advancement of cannabinoid analogs for drug discovery purposes. Exozymes Inc. is a biotechnology company focused on drug discovery.
